Chardan Capital Maintains Buy Rating for ProQR Therapeutics
Chardan Capital reiterated its Buy rating on ProQR Therapeutics with a price target of $3, a 63.93% upside from the current price.
Key Points
- Chardan Capital reiterated its Buy rating on ProQR Therapeutics with a $3 price target on June 26, 2026.
- Chardan Capital's $3 price target implies 63.93% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.83 share price.
- Shares of NasdaqCM:PRQR traded near $1.56 on Saturday, with a market cap of approximately $161.2 million.
- Peers like Aberdeen Group PLC increased their holdings by 12.4%, while Sio Capital Management reduced theirs by 9.7%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital reiterated its Buy rating for ProQR Therapeutics N.V. (NasdaqCM:PRQR) on June 26, 2026, setting a price target of $3. The biotechnology company's stock traded near $1.56 on Saturday.
Other Institutional Activity in ProQR Therapeutics
Among ProQR's institutional investors, Aberdeen Group PLC increased its holdings by 366,289 shares, bringing its total to 3,316,965 shares valued at approximately $5.37 million. Privium Fund Management B.V. added 109,387 shares, ending with 5,467,149 shares worth about $8.86 million, marking a 2.0% increase. On the other hand, Sio Capital Management, LLC reduced its stake by 209,466 shares, a 9.7% decrease, leaving them with 1,954,715 shares valued at $3.17 million.
ProQR Therapeutics N.V. Stock Down 20.1%
Shares of ProQR Therapeutics traded near $1.56 on Saturday. The company has a market cap of approximately $161.2 million. It operates with a forward P/E ratio that isn't meaningful due to its lack of profitability, and a beta of 0.061 suggests low volatility. The stock's 52-week range is between $1.33 and $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR maintains a current ratio of 2.481 and a quick ratio of 2.39, with a debt-to-equity ratio of 41.845.
$PRQR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ProQR Therapeutics reported revenue of $13.64 million, reflecting a decline of 57.1%. The company posted a negative EPS of $0.49, with a net margin of 0.0% and a return on equity of -78.1%. The next earnings release is expected on August 6, 2026.
Insider Buying and Selling at ProQR Therapeutics N.V.
On June 2, 2026, insider Hinsch Gylvin Lykke purchased 14,495 shares, though the transaction was not part of a planned trading program.
Analysts Set New Price Targets
On June 26, 2026, Jones Trading maintained a Buy rating with a $10 price target. Chardan Capital also maintained its Buy rating with a $3 target. The consensus among analysts is a Buy recommendation, with an average target price of $8.88.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a biotechnology company based in Leiden, Netherlands. It focuses on developing RNA editing therapies for genetic disorders. Their Axiomer RNA editing platform aims to treat diseases such as cholestatic conditions and Rett syndrome. The company collaborates with Eli Lilly and Company to explore new treatments for liver and nervous system disorders. ProQR was founded in 2012 and is led by CEO Daniel Anton de Boer.
Bottom Line
Chardan Capital's reiteration of its Buy rating for ProQR Therapeutics reflects ongoing interest in the company's potential. Investors track these analyst opinions closely, though it's important to remember that these ratings are based on past data. Keep an eye on ProQR's next earnings report for further insights.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.